Sientra (SIEN) Hits New 1-Year High and Low at $21.06

Share on StockTwits

Shares of Sientra (NASDAQ:SIEN) reached a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $21.06 and last traded at $20.31, with a volume of 18896 shares traded. The stock had previously closed at $20.86.

Several analysts recently weighed in on the company. Canaccord Genuity restated a “buy” rating and set a $19.00 price objective on shares of Sientra in a research report on Thursday, May 10th. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, June 7th. ValuEngine downgraded Sientra from a “hold” rating to a “sell” rating in a research report on Thursday, February 22nd. Leerink Swann restated an “outperform” rating on shares of Sientra in a research report on Friday, April 20th. Finally, Maxim Group downgraded Sientra from a “buy” rating to a “hold” rating in a research report on Friday, June 8th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $16.29.

The company has a debt-to-equity ratio of 2.31, a current ratio of 1.21 and a quick ratio of 0.71. The stock has a market capitalization of $560.00 million, a price-to-earnings ratio of -7.38 and a beta of -0.95.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Wednesday, May 9th. The medical instruments supplier reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.15). Sientra had a negative return on equity of 181.25% and a negative net margin of 164.72%. The business had revenue of $14.60 million for the quarter, compared to the consensus estimate of $14.49 million. During the same quarter in the prior year, the company earned $0.61 earnings per share. Sientra’s quarterly revenue was up 95.2% compared to the same quarter last year. equities analysts forecast that Sientra will post -2.64 EPS for the current year.

In other news, CFO Patrick F. Williams bought 7,408 shares of the company’s stock in a transaction on Monday, May 7th. The stock was purchased at an average cost of $13.50 per share, for a total transaction of $100,008.00. Following the completion of the transaction, the chief financial officer now owns 57,408 shares of the company’s stock, valued at $775,008. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director R Scott Greer bought 11,111 shares of the company’s stock in a transaction on Monday, May 7th. The stock was purchased at an average price of $13.50 per share, with a total value of $149,998.50. Following the completion of the transaction, the director now directly owns 52,657 shares of the company’s stock, valued at approximately $710,869.50. The disclosure for this purchase can be found here. Insiders acquired 301,853 shares of company stock valued at $4,075,016 over the last quarter. Corporate insiders own 31.00% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Deutsche Bank AG raised its position in Sientra by 24.9% in the fourth quarter. Deutsche Bank AG now owns 33,499 shares of the medical instruments supplier’s stock valued at $470,000 after purchasing an additional 6,669 shares during the last quarter. BlackRock Inc. raised its position in Sientra by 1.2% in the first quarter. BlackRock Inc. now owns 767,308 shares of the medical instruments supplier’s stock valued at $7,411,000 after purchasing an additional 8,796 shares during the last quarter. Two Sigma Investments LP raised its position in Sientra by 120.1% in the fourth quarter. Two Sigma Investments LP now owns 32,382 shares of the medical instruments supplier’s stock valued at $455,000 after purchasing an additional 17,668 shares during the last quarter. Barclays PLC raised its position in Sientra by 133.7% in the first quarter. Barclays PLC now owns 31,521 shares of the medical instruments supplier’s stock valued at $304,000 after purchasing an additional 18,033 shares during the last quarter. Finally, Quantum Capital Management raised its position in Sientra by 31.5% in the first quarter. Quantum Capital Management now owns 87,823 shares of the medical instruments supplier’s stock valued at $848,000 after purchasing an additional 21,050 shares during the last quarter. Hedge funds and other institutional investors own 57.28% of the company’s stock.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Axiom Price Reaches $0.0078 on Exchanges
Axiom Price Reaches $0.0078 on Exchanges
Starta Hits 24-Hour Trading Volume of $0.00
Starta Hits 24-Hour Trading Volume of $0.00
Zacks: Brokerages Expect MTS Systems Co.  Will Announce Earnings of $0.63 Per Share
Zacks: Brokerages Expect MTS Systems Co. Will Announce Earnings of $0.63 Per Share
Obalon Therapeutics  Getting Somewhat Positive Media Coverage, Study Shows
Obalon Therapeutics Getting Somewhat Positive Media Coverage, Study Shows
Novus Therapeutics  Receives News Impact Score of 0.16
Novus Therapeutics Receives News Impact Score of 0.16
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc  This Quarter
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc This Quarter


Leave a Reply

 
© 2006-2018 Zolmax.